Selpercatinib Approved for RET Fusion–Positive Solid Tumors

The FDA has granted accelerated approval to selpercatinib (Retevmo®, Eli Lilly and Company) for treatment of adult patients with locally advanced or metastatic rearranged during transfection (RET) gene fusion solid tumors that have progressed on prior systemic therapy, or who have no adequate alternative treatment options. "Selpercatinib, a highly selective RET kinase inhibitor with central nervous system (CNS) activity, was developed specifically to treat patients with RET-altered cancers," wro...

Continue reading

FDA Approves Dostarlimab-Gxly for Mismatch Repair Deficient Advanced Solid Tumors

The FDA has granted accelerated approval to dostarlimab-gxly (Jemperli, GlaxoSmithKline) for patients with mismatch repair deficient (dMMR) recurrent or advanced solid tumors that have progressed on or following prior treatment and have no other satisfactory alternative options. In addition, the FDA approved the VENTANA MMR RxDx Panel as a companion diagnostic to determine eligibility for treatment with dostarlimab. "Dostarlimab is an investigational, humanized programmed cell death protein 1 (P...

Continue reading

Copyright © 2022 Oncology Data Advisor. All rights reserved.